The approval is the strongest challenge yet to Pfizer’s pneumococcal vaccine franchise, led by its 20-valent Prevnar 20 shot, which generated $6.4 billion in sales last year from use for ...

Among them are data from the phase III STRIDE-3 study, which evaluated Capvaxive compared to PCV20 (pneumococcal 20-valent conjugate vaccine) in adults aged 18 years and above who had not ...

The CHMP’s recommendation was based on results from the late-stage STRIDE-3 trial, which compared Capvaxive to Pfizer’s 20-valent vaccine (PCV20) in adults who had not previously received a ...

However, sustainability is likely to depend on disease surveillance data, which is also critical for the introduction of higher valency conjugate or protein-based pneumococcal vaccines when they ...

the serotypes covered by CAPVAXIVE are responsible for more cases of IPD in adults compared to PCV20 (pneumococcal 20-valent conjugate vaccine): Data were included for select countries based on EU ...

Based on country-level data from the following four EU countries, the serotypes covered by CAPVAXIVE are responsible for more cases of IPD in adults compared to PCV20 (pneumococcal 20-valent conjugate ...